



FR-188582

**Catalog No: tcsc7185** 

且	Available Sizes
Size	1mg
Size	5mg
Size	10mg
Size	20mg
	Specifications
<b>CAS</b> 1896	<b>No:</b> 99-82-9
Form	iula: 13 <sup>CIN</sup> 2 <sup>O</sup> 2 <sup>S</sup>
<b>Path</b> Immu	<b>way:</b> Inology/Inflammation
<b>Targ</b> COX	et:
<b>Purit</b> >98%	y / Grade:
	<b>bility:</b> M in DMSO
Obse	erved Molecular Weight:

## **Product Description**

332.8

FR-188582 is a highly selective inhibitor of cyclooxygenase (COX)-2, with an  $IC_{50}$  value of 17 nM.





IC50 & Target: IC50: 17 nM (COX-2)<sup>[1]</sup>

In Vitro: In a recombinant human cyclooxygenase (COX) enzyme activity, FR-188582 (FR188582) inhibits COX-2 with an IC<sub>50</sub> value of 17 nM, and the inhibition of prostaglandin (PG) E2 formation by FR188582 isover 6000 times more selective for COX-2 than COX-1 [1]

In Vivo: Oral administration of FR-188582 (0.01-3.2 mg/kg) reverses paw edema in adjuvant arthritic rats and shows a therapeutic effect in a dose-dependent manner with  $ED_{50}$  values (95% C.L.) of 0.074 (0.00021-0.53) and 0.063 (0.0039-0.31) mg/kg for adjuvant-injected paws and adjuvant-uninjected paws, respectively. The anti-inflammatory effect of FR-188582 (FR188582) is threefold more potent than that of Indomethacin with  $ED_{50}$  values (95% C.L.) of 0.24 (0.047-1.8) and 0.20 (0.021-0.79) mg/kg for adjuvant-injected paws and adjuvant-uninjected paws, respectively<sup>[1]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!